Figure 2.
A. Patient #4 pre-treatment CT abdomen/pelvis demonstrating large right renal mass. B. Significant interval reduction in the size of the primary renal mass after three cycles of ipilimumab/nivolumab combination therapy followed by pembrolizumab/axitinib for 13 cycles.